PT  - JOURNAL ARTICLE
AU  - Johnson, Emma C
AU  - Austin-Zimmerman, Isabelle
AU  - Thorpe, Hayley HA
AU  - Levey, Daniel F
AU  - Baranger, David AA
AU  - Colbert, Sarah MC
AU  - Demontis, Ditte
AU  - Khokhar, Jibran Y
AU  - Davis, Lea K
AU  - Edenberg, Howard J
AU  - Di Forti, Marta
AU  - Sanchez-Roige, Sandra
AU  - Gelernter, Joel
AU  - Agrawal, Arpana
TI  - Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking
AID  - 10.1101/2024.01.17.24301430
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.17.24301430
4099  - http://medrxiv.org/content/early/2024/01/18/2024.01.17.24301430.short
4100  - http://medrxiv.org/content/early/2024/01/18/2024.01.17.24301430.full
AB  - Individuals with schizophrenia frequently experience co-occurring substance use, including tobacco smoking and heavy cannabis use, and substance use disorders. There is interest in understanding the extent to which these relationships are causal, and to what extent shared genetic factors play a role. We explored the relationships between schizophrenia (Scz), cannabis use disorder (CanUD), and ever-regular tobacco smoking (Smk) using the largest available genome-wide studies of these phenotypes in individuals of African and European ancestries. All three phenotypes were positively genetically correlated (rgs = 0.17 – 0.62).Causal inference analyses suggested the presence of horizontal pleiotropy, but evidence for bidirectional causal relationships was also found between all three phenotypes even after correcting for horizontal pleiotropy. We identified 439 pleiotropic loci in the European ancestry data, 150 of which were novel (i.e., not genome-wide significant in the original studies). Of these pleiotropic loci, 202 had lead variants which showed convergent effects (i.e., same direction of effect) on Scz, CanUD, and Smk. Genetic variants convergent across all three phenotypes showed strong genetic correlations with risk-taking, executive function, and several mental health conditions. Our results suggest that both horizontal pleiotropy and causal mechanisms may play a role in the relationship between CanUD, Smk, and Scz, but longitudinal, prospective studies are needed to confirm a causal relationship.Competing Interest StatementJ.G. is a holder of US patent 10,900,082 titled: "Genotype-guided dosing of opioid agonists", issued 26 January 2021. J.G. is paid for their editorial work on the journal Complex Psychiatry.Funding StatementECJ received support from K01DA051759. DAAB received funding from K99AA030808. JYK received support from a Canada Research Chair in Translational Neuropsychopharmacology (CIHR). HHAT is funded by a Canadian Institutes of Health Research Postdoctoral Fellowship. SSR was supported by T32IR5226 and DP1DA054394. DFL received support from 1IK2BX005058-01A2. JG received support from R01DA058862.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in this study are available for download from the PGC website (https://pgc.unc.edu/for-researchers/download-results/), the GSCAN website (https://conservancy.umn.edu/handle/11299/241912), and the Gelernter lab website (https://medicine.yale.edu/lab/gelernter/stats/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be made available upon publication at the following link: https://github.com/WashU-BG/CanUD_Smk_Scz